These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37756479)

  • 41. CFTR mutations and cystic fibrosis.
    Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
    [No Abstract]   [Full Text] [Related]  

  • 42. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The frequency of the delta F508 mutation in the cystic fibrosis genes of 71 unrelated South African cystic fibrosis patients.
    Herbert JS; Retief AE
    S Afr Med J; 1992 Jul; 82(1):13-5. PubMed ID: 1641711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transformative mutation specific pharmacotherapy for cystic fibrosis.
    Sanders DB; Farrell PM
    BMJ; 2012 Jan; 344():e79. PubMed ID: 22232540
    [No Abstract]   [Full Text] [Related]  

  • 45. A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants.
    Wainwright CE
    Am J Respir Crit Care Med; 2022 Nov; 206(10):1193-1195. PubMed ID: 35856818
    [No Abstract]   [Full Text] [Related]  

  • 46. Targeting the basic defect in cystic fibrosis.
    Welsh MJ
    N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
    [No Abstract]   [Full Text] [Related]  

  • 47. Simplifying CFTR modulation therapy in cystic fibrosis.
    Arch Dis Child; 2023 Aug; 108(8):615. PubMed ID: 37468145
    [No Abstract]   [Full Text] [Related]  

  • 48. Determination of cystic fibrosis carrier frequency for Zuni native Americans of New Mexico.
    Kessler D; Moehlenkamp C; Kaplan G
    Clin Genet; 1996 Feb; 49(2):95-7. PubMed ID: 8740921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
    Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
    J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
    [No Abstract]   [Full Text] [Related]  

  • 50. New drug treatments for cystic fibrosis.
    Smyth RL
    BMJ; 2020 Jan; 368():m118. PubMed ID: 31959620
    [No Abstract]   [Full Text] [Related]  

  • 51. A lesson in participatory research for a rare mutation of cystic fibrosis.
    Kramer-Golinkoff E
    J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S808-9. PubMed ID: 25029983
    [No Abstract]   [Full Text] [Related]  

  • 52. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.
    Gelman MS; Kopito RR
    J Clin Invest; 2002 Dec; 110(11):1591-7. PubMed ID: 12464661
    [No Abstract]   [Full Text] [Related]  

  • 54. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis.
    Hamilton JW
    Lancet; 2001 Dec; 358(9298):2014-6. PubMed ID: 11755605
    [No Abstract]   [Full Text] [Related]  

  • 55. Amiloride for lung disease in cystic fibrosis.
    Zahaykevich A
    DICP; 1991 Dec; 25(12):1340-1. PubMed ID: 1815431
    [No Abstract]   [Full Text] [Related]  

  • 56. Cystic fibrosis: CFTR modulators and their mechanism of action.
    Nieddu E
    Curr Pharm Des; 2013; 19(19):3474-5. PubMed ID: 23331031
    [No Abstract]   [Full Text] [Related]  

  • 57. Orphan cystic fibrosis drugs find sister diseases.
    Dolgin E
    Nat Med; 2011 Apr; 17(4):397. PubMed ID: 21475214
    [No Abstract]   [Full Text] [Related]  

  • 58. Highlights from the 2019 North American Cystic Fibrosis Conference.
    Hoppe JE; Guimbellot J; Martiniano SL; Toprak D; Davis C; Daines CL; Muhlebach MS; Esther CR; Dellon EP
    Pediatr Pulmonol; 2020 Sep; 55(9):2225-2232. PubMed ID: 32573948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 60. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.